Conclusions: Approximately one-third of patients with advanced CKD and significant LVSD were not receiving optimal pharmacotherapy, in the absence of known contraindication or intolerance. Identifying and overcoming barriers to care will be crucial in order to enhance the management of this high-risk population.
PMID: 20349421 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)